We are delighted to announce Cedric Bogaert as a touchIMMUNOLOGY Future Leader 2026, selected by peers as one of the immunologists changing the future of precision medicine.
Cedric Bogaert is a bioscience engineer with expertise in medical genetics, precision diagnostics, and immunotherapy, with experience spanning genomic profiling and personalized healthcare innovation. In 2018, he co-founded myNEO Therapeutics and currently serves as Acting Manager (CEO), leading the company’s continued growth and development in antigen discovery and personalized immunotherapy.
Cedric Bogaert has been recognized in Forbes 30 Under 30 and Deloitte FAST50, and is a recipient of the Sciacca Medical Award for his contributions to healthcare innovation.
In this Q&A, Cedric outlines what led him to a career at the intersection of science and technology, the most rewarding moments in his career so far, and the advice he would give to students and early-career professionals who are considering a career in precision immunology.
New insights are added regularly, covering a broad range of subspecialties and evolving clinical scenarios. Sign up below for Free Access to the latest clinical updates in your specialty!
What led you to build a career at the intersection of science and technology?
From a young age, I was drawn to both science and computational technology. Rather than choosing one over the other, I was interested in the space where they come together, where technology can unlock new scientific insights and applications.
That naturally shaped my career path. Today, I’m proud that together with my co-founders, team, and shareholders, we’ve been able to contribute at that intersection. Not just by advancing the field, but also by creating tangible impact for stakeholders such as biopharma partners and, ultimately, patients in clinical settings.
What has been the most rewarding moment in your journey so far?
There hasn’t been a single defining moment, but rather a series of milestones along the way.
One of the most rewarding aspects has been seeing the team grow over the past seven years into true experts in immunology and immuno-oncology, presenting at leading conferences and engaging with peers at a very high level. External recognition such as Forbes, Deloitte FAST50, and the Sciacca Medical Award has also been meaningful validation of that journey.
A key turning point was our first partnership with CureVac. That collaboration confirmed both our vision and the value we had been building.
Ultimately, the most meaningful moment was seeing the first patients treated with immunogenic tumor targets identified through our platform. That is what the entire team worked towards and what we are most proud of.
What advice would you give to medical students or young professionals considering a career in precision immunology?
Build your own path. Precision immunology is still an emerging field, and there is a long way to go before its full potential is realized. That means there is room for contributions from many different domains, including research, computational work, regulatory, legal, and manufacturing.
What makes this field particularly exciting is the number of open challenges. It allows people to take ownership, focus on specific problems, and contribute in a very tangible way. In that sense, many roles feel like being a micro-entrepreneur within a larger ecosystem.
If you are motivated by impact and complexity, it is a uniquely rewarding space, because your work can directly help shape the future of medicine.
More content in immunology.
Cite: Cedric Bogaert on the intersection of precision diagnostics and immunotherapy: touchIMMUNOLOGY Future Leaders 2026. touchIMMUNOLOGY. 21 May 2026.
Disclosures: This short article was prepared by touchIMMUNOLOGY in collaboration with Cedric Bogaert. No fees or funding were associated with its publication.
